Purified recombinant proteins and DNA plasmids that express these proteins are at the core of modern biologics research, development, and products, and the discovery and development of small molecule drugs. Rapid translation of the enormous numbers of discoveries in genomics, proteomics and high throughput screening into potential commercial products such as drugs, vaccines, and diagnostics requires a robust, high quality protein development and production process that takes molecules from discovery through initiation of clinical trials.

Contract Products and Services:
Protein Potential provides pharmaceutical and biotechnology companies, and government and academic institutions with high quality, purified Protein PotentialTM recombinant proteins and DNA plasmids for research and development. Protein Potential also provides process development, documentation, and technological know-how to transition therapeutic, vaccine, diagnostic proteins and DNA plasmids to large scale cGMP (current Good Manufacturing Practices) manufacture (Protein Potential, SM service packages).

Protein Potential's competitive advantage is its experience and capabilities to rapidly and efficiently take newly discovered molecules through all of the steps required to initiate a clinical trial. These include initial protein expression, enhanced protein expression, process development for cGMP manufacture, development of analytical assays, transition to a cGMP site, and other processes for investigational new drug (IND) enabling studies. The principal members of Protein Potentials staff have been responsible for the cGMP manufacture of tens of kilograms of purified recombinant proteins that have been administered intravenously to patients.

Protein Potential offers customized packages of purified proteins (milligram to gram quantities), development and testing of analytical assays, development of manufacturing processes, process development documentation, consultation, and hands-on involvement in a highly competitive timeframe and at a fair price.

Research and Development:
Protein Potential has established a research and development program to produce intellectual property and DNA and protein products. We have initiated a program to produce vaccines for SARS, dengue fever, tularemia, Plasmodium falciparum malaria and Plasmodium vivax malaria.

Protein Potential's Research and Development group focuses on vaccine development. It has internal programs intended to produce vaccines for Plasmodium vivax malaria, Plasmodium falciparum malaria, SARS, dengue fever, tularemia, and plague. Protein Potential's Products and Services group provides pharmaceutical and biotechnology companies, and government and academic institutions with high quality, recombinant proteins and DNA plasmids. Protein Potential also provides process development, documentation, and technological know-how to transition therapeutic proteins, whole organism and subunit vaccines, and diagnostic proteins to large scale manufacture under cGMP conditions; manufactures under cGMP and develops and conducts validated assays required to release vaccines for clinical use and assess their immunogenicity in humans (Protein Potential service packages).